Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 10 of 10« First...678910

Merrimack CEO Resigns, Company Slashes Jobs

Robert Mulroy, CEO of Merrimack Pharmaceuticals, has resigned his position as part of a corporate restructuring move that will result in a 22 percent workforce reduction.

Read More »

AstraZeneca licenses inflammatory disease candidate to Allergan

Britain’s AstraZeneca said it had licensed a potential medicine for inflammatory diseases to Allergan for an upfront payment of $250 million and potential additional payments of up to $1.27 billion.

Read More »

Big Pharma vs Big Pharma in court battles over biosimilar drugs

The line dividing makers of brand-name drugs and copycat medicines is blurring as companies known for innovative treatments queue up to peddle copies of rivals’ complex biological medicines.

Read More »

J&J psoriasis drug tops placebo, Humira in late stage study

An experimental biotech drug developed by Johnson & Johnson proved more effective at clearing moderate-to-severe cases of the skin condition plaque psoriasis than a placebo or AbbVie Inc.’s big-selling Humira, according to data from a late-stage study.

Read More »

Page 10 of 10« First...678910

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom